Morgan Stanley Cuts Biogen (NASDAQ:BIIB) Price Target to $152.00

Biogen (NASDAQ:BIIB – Free Report) had its price objective decreased by Morgan Stanley from $157.00 to $152.00 in a research note published on Wednesday,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock. Several other equities research analysts have also recently issued reports on BIIB. Stifel Nicolaus cut shares of […]